Skip to main content
Erschienen in: Clinical Rheumatology 7/2013

01.07.2013 | Brief Report

Is rheumatoid factor useful in primary care? A retrospective cross-sectional study

verfasst von: Anne Miller, Kamal R. Mahtani, Margaret A. Waterfield, Anthony Timms, Siraj A. Misbah, Raashid A. Luqmani

Erschienen in: Clinical Rheumatology | Ausgabe 7/2013

Einloggen, um Zugang zu erhalten

Abstract

Rheumatoid factor (RF) is frequently tested in general practice where its utility as a diagnostic test for rheumatoid arthritis (RA) is not known. We undertook a retrospective cross-sectioal study to determine the utility and cost of RF in a primary care population. We compared RF with recorded clinical features based on the American College of Rheumatology (ACR) criteria as a diagnostic test for RA in 235 patients in general practice using receiver operating characteristic curves and calculated the cost of testing per case of RA. We analysed 36,191 RF requests made to one laboratory from 2003–2009 at a mean annual cost of £58,164 and the variation and annual cost of RF testing between 77 practices. The sensitivity and specificity of RF at the optimal cut-off value of 20 U/ml were 0.6 and 0.96 and that of two documented clinical ACR criteria were 0.9 and 0.92, respectively. No ACR criteria were documented in 150 (63.8 %) patients who had RF tested. The overall cost of RF testing per case of seropositive RA was £708.75. Of all RF requests, 66.6 % was made by GPs, 7.0 % by rheumatologists and 26.4 % by other hospital departments. The proportion of positive tests was 5.8 % in primary care and 17.7 % in rheumatology. The mean number of tests performed annually in primary care was 4.65 (SD 2.7) per 1,000 patients. RF is less sensitive for RA than clinical features in primary care and is frequently requested in cases without clinical evidence of the disease, adding to the overall cost.
Literatur
1.
Zurück zum Zitat Farragher TM, Lunt M, Fu B, Bunn D, Symmons DP (2010) Early treatment with, and time receiving, first disease-modifying antirheumatic drug predicts long-term function in patients with inflammatory polyarthritis. Ann Rheum Dis 69(4):689–695PubMedCrossRef Farragher TM, Lunt M, Fu B, Bunn D, Symmons DP (2010) Early treatment with, and time receiving, first disease-modifying antirheumatic drug predicts long-term function in patients with inflammatory polyarthritis. Ann Rheum Dis 69(4):689–695PubMedCrossRef
2.
Zurück zum Zitat van der Linden MP, le Cessie S, Raza K, van der Woude D, Knevel R, Huizinga TW et al (2010) Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum 62(12):3537–3546PubMedCrossRef van der Linden MP, le Cessie S, Raza K, van der Woude D, Knevel R, Huizinga TW et al (2010) Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum 62(12):3537–3546PubMedCrossRef
3.
Zurück zum Zitat Thomas MJ, Adebajo A, Chapel HM, Webley M (1995) The use of rheumatoid factors in clinical practice. Postgrad Med J 71(841):674–677PubMedCrossRef Thomas MJ, Adebajo A, Chapel HM, Webley M (1995) The use of rheumatoid factors in clinical practice. Postgrad Med J 71(841):674–677PubMedCrossRef
4.
Zurück zum Zitat Sinclair D, Hull RG (2003) Why do general practitioners request rheumatoid factor? A study of symptoms, requesting patterns and patient outcome. Ann Clin Biochem 40(Pt 2):131–137PubMedCrossRef Sinclair D, Hull RG (2003) Why do general practitioners request rheumatoid factor? A study of symptoms, requesting patterns and patient outcome. Ann Clin Biochem 40(Pt 2):131–137PubMedCrossRef
5.
Zurück zum Zitat Sokka T, Pincus T (2009) Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35 %–45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States. J Rheumatol 36(7):1387–1390PubMedCrossRef Sokka T, Pincus T (2009) Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35 %–45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States. J Rheumatol 36(7):1387–1390PubMedCrossRef
6.
Zurück zum Zitat Bukhari M, Lunt M, Harrison BJ, Scott DGI, Symmons DPM, Silman AJ (2002) Erosions in inflammatory polyarthritis are symmetrical regardless of rheumatoid factor status: results from a primary care-based inception cohort of patients. Rheumatology 41(3):246–252PubMedCrossRef Bukhari M, Lunt M, Harrison BJ, Scott DGI, Symmons DPM, Silman AJ (2002) Erosions in inflammatory polyarthritis are symmetrical regardless of rheumatoid factor status: results from a primary care-based inception cohort of patients. Rheumatology 41(3):246–252PubMedCrossRef
7.
Zurück zum Zitat van Schaardenburg D, Lagaay AM, Otten HG, Breedveld FC (1993) The relation between class-specific serum rheumatoid factors and age in the general population. Br J Rheumatol 32(7):546–549PubMedCrossRef van Schaardenburg D, Lagaay AM, Otten HG, Breedveld FC (1993) The relation between class-specific serum rheumatoid factors and age in the general population. Br J Rheumatol 32(7):546–549PubMedCrossRef
8.
Zurück zum Zitat Husby G, Gran JT, Johannessen A (1988) Epidemiological and genetic aspects of IgM rheumatoid factors. Scand J Rheumatol Suppl 75:213–218PubMedCrossRef Husby G, Gran JT, Johannessen A (1988) Epidemiological and genetic aspects of IgM rheumatoid factors. Scand J Rheumatol Suppl 75:213–218PubMedCrossRef
9.
Zurück zum Zitat Nielson SF, Bojesen SE, Schnohr P, Nordestgaard BG (2012) Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study. BMJ 345:e5244. doi:10.1136/bmj.e5244 CrossRef Nielson SF, Bojesen SE, Schnohr P, Nordestgaard BG (2012) Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study. BMJ 345:e5244. doi:10.​1136/​bmj.​e5244 CrossRef
10.
Zurück zum Zitat Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S et al (2007) Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146(11):797–808PubMedCrossRef Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S et al (2007) Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146(11):797–808PubMedCrossRef
11.
Zurück zum Zitat National Institute for Health and Clinical Excellence (2009) Rheumatoid arthritis: the management of rheumatoid arthritis in adults. National Institute for Health and Clinical. Excellence - Clinical Guidelines, London National Institute for Health and Clinical Excellence (2009) Rheumatoid arthritis: the management of rheumatoid arthritis in adults. National Institute for Health and Clinical. Excellence - Clinical Guidelines, London
12.
Zurück zum Zitat Luqmani R, Hennell S, Estrach C, Basher D, Birrell F, Bosworth A et al (2009) British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology (Oxford) 48(4):436–439CrossRef Luqmani R, Hennell S, Estrach C, Basher D, Birrell F, Bosworth A et al (2009) British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology (Oxford) 48(4):436–439CrossRef
13.
Zurück zum Zitat Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324PubMedCrossRef Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324PubMedCrossRef
14.
Zurück zum Zitat Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581PubMedCrossRef Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581PubMedCrossRef
15.
Zurück zum Zitat Xu D, Groom C (2009) Economic models of identification and treatment of early rheumatoid arthritis. National Audit Office, London Xu D, Groom C (2009) Economic models of identification and treatment of early rheumatoid arthritis. National Audit Office, London
16.
Zurück zum Zitat van der Weijden T, van Bokhoven MA, Dinant GJ, van Hasselt CM, Grol RP (2002) Understanding laboratory testing in diagnostic uncertainty: a qualitative study in general practice. Br J Gen Pract 52(485):974–980PubMed van der Weijden T, van Bokhoven MA, Dinant GJ, van Hasselt CM, Grol RP (2002) Understanding laboratory testing in diagnostic uncertainty: a qualitative study in general practice. Br J Gen Pract 52(485):974–980PubMed
17.
Zurück zum Zitat Gran JT, Nordvag BY (2000) Referrals from general practice to an outpatient rheumatology clinic: disease spectrum and analysis of referral letters. Clin Rheumatol 19(6):450–454PubMedCrossRef Gran JT, Nordvag BY (2000) Referrals from general practice to an outpatient rheumatology clinic: disease spectrum and analysis of referral letters. Clin Rheumatol 19(6):450–454PubMedCrossRef
18.
Zurück zum Zitat Suarez-Almazor ME, Gonzalez-Lopez L, Gamez-Nava JI, Belseck E, Kendall CJ, Davis P (1998) Utilization and predictive value of laboratory tests in patients referred to rheumatologists by primary care physicians. J Rheumatol 25(10):1980–1985PubMed Suarez-Almazor ME, Gonzalez-Lopez L, Gamez-Nava JI, Belseck E, Kendall CJ, Davis P (1998) Utilization and predictive value of laboratory tests in patients referred to rheumatologists by primary care physicians. J Rheumatol 25(10):1980–1985PubMed
19.
Zurück zum Zitat Spector TD, Hart DJ, Powell RJ (1993) Prevalence of rheumatoid arthritis and rheumatoid factor in women: evidence for a secular decline. Ann Rheum Dis 52(4):254–257PubMedCrossRef Spector TD, Hart DJ, Powell RJ (1993) Prevalence of rheumatoid arthritis and rheumatoid factor in women: evidence for a secular decline. Ann Rheum Dis 52(4):254–257PubMedCrossRef
Metadaten
Titel
Is rheumatoid factor useful in primary care? A retrospective cross-sectional study
verfasst von
Anne Miller
Kamal R. Mahtani
Margaret A. Waterfield
Anthony Timms
Siraj A. Misbah
Raashid A. Luqmani
Publikationsdatum
01.07.2013
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 7/2013
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-013-2236-0

Weitere Artikel der Ausgabe 7/2013

Clinical Rheumatology 7/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.